Jeremy Bender, Day One Biopharmaceuticals CEO
Two days after showing strong pediatric cancer data, Day One taps $150M in public capital
Public biotechs can still raise money, but it comes with a big caveat: The clinical data must impress.
It appears the market reacted so with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.